Women with breast cancer who took statins regularly had significantly better breast cancer-specific survival than those who did not take any statins, a Swedish study has shown. [SABCS 2017, poster P2-13-03]
A recent study presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) showed that acupuncture is effective in reducing aromatase inhibitor–induced joint symptoms among breast cancer patients.
Adding trastuzumab to standard adjuvant chemotherapy does not improve survival or reduce recurrence in patients with early-stage breast cancer expressing low levels of HER2, according to results of a National Surgical Adjuvant Breast and Bowel Project study reported at the 2017 San Antonio Breast Cancer Symposium (SABCS).
The phase IB/II PANACEA study recently showed that the addition of pembrolizumab to trastuzumab in patients with trastuzumab-resistant advanced HER2-positive breast cancer resulted in disease control with a tolerable safety profile.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Incorporating basic tumour characteristics, such as hormone receptor status and tumour origin, improves the power of the cell-loss metric to predict response to treatment, according to a new study presented at the recently concluded 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).